Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Starting soon Observational

A Complex Health Promotion Intervention in Parasport - The Safe & Healthy Parasport Project

NCT05317130 · tracked via the Priya Life Science Sweden tracker
Phase
Observational
Started
2022-09-01
Last updated
2022-04-07

Condition(s) studied

Sport InjuryDiabetesHealth BehaviorIllness BehaviorLiteracy

Investigational drug(s) / intervention(s)

Athlete health monitoring

Athlete health monitoring: Observational study

Study summary

The interest in Para sport is steadily increasing. A concern is, though, that elite Para athletes report a high incidence of injuries and illnesses. Altogether, there is an urgent need to prevent such incidents among athletes already suffering from an impairment. However, most of the existing training-based prevention programmes are not adapted or accessible to Para athletes. Also, recent research suggests that sports safety work advantageously should facilitate disease prevention and health promotion. Such intervention would hypothetically also have the potential to reduce injuries, illnesses and improve health among Para athletes. To allow full implementation, the intervention would need to be adapted to the Para athletes´ various impairments, abilities and sports.

MAIN QUESTIONS TO BE ADRESSED

* Can an evidence-based eHealth health promotion platform prevent sports injuries and illnesses in elite para athletes over 6 months, 12 months and 5 years?
* Can such platform improve overall health parameters such as sleep, nutrition and mental health in elite para athletes and influence the performance parameters training quantity and training quality over 6 months, 12 months and 5 years?
* Can such platform improve health literacy among Para athletes?

Eligibility

Sex
ALL
Min age
18 Years
Max age
66 Years
Healthy volunteers
No
Inclusion Criteria: * Being an registered para athlete in Sweden or South Africa * Having an athlete classification according to the International Paralympic Committee Exclusion Criteria: * Age below 18 years, or older than 66 * Being a non-classified athlete

Primary outcome measure(s)

  • Incidence of sports injuries and illnesses 6 months following study start — The incidence will be followed up 6 months following study start
    The incidence of sports injuries and illnesses is the primary outcome. Incidence data will be calculated as the number of injuries and illnesses per 1000 hours of sports exposure.
  • Incidence of sports injuries and illnesses 12 months following study start — The incidence will be followed up 12 months following study start
    The incidence of sports injuries and illnesses is the primary outcome. Incidence data will be calculated as the number of injuries and illnesses per 1000 hours of sports exposure.
  • Incidence of sports injuries and illnesses 4 years following study start — The incidence will be followed up 4 years following study start
    The incidence of sports injuries and illnesses is the primary outcome. Incidence data will be calculated as the number of injuries and illnesses per 1000 hours of sports exposure.

Trial sites (1)

FacilityCityRegionStatus
Lund University Lund Skåne County
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05317130 on ClinicalTrials.gov ↗ ← All trials in Sweden